The Society welcomes NICEs endorsement of lebrikizumab as an additional treatment option for eligible individuals with moderate to severe atopic eczema, emphasizing the importance of providing diverse treatment choices to match patients needs. Jorgen Damsbo, General Manager at Almirall, UK, remarked, The NICE recommendation for lebrikizumab reflects its proven effectiveness with 4-weekly maintenance dosing and a favorable safety profile, aligning with our commitment to improving patients lives by helping them achieve better health. Professor Tony Bewley, Consultant Dermatologist at Barts Health NHS Trust and Honorary Professor of Dermatology at QMUL, emphasized the significant psychosocial burden of atopic dermatitis, noting that lebrikizumabs approval marks a crucial advancement that is welcomed by both patients and clinicians
& Yasuda, S
Monthly costs typically range from $900 to $1,500 for brand-name products, making long-term therapy financially prohibitive for many patients
First, there is a lack of standardized exercise protocols across studies, with wide variability in training type, frequency, intensity, and supervision, which limits comparability and prevents the identification of optimal regimens for preserving lean mass or enhancing metabolic outcomes